In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus
ACS Omega · 25.06.2024 · 9 (25) · 27632-27642
DOI: 10.1021/acsomega.4c03417 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 13.06.2024. Verfasst von Vitor W Rabelo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro CEP 24210-201,…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico.
Abstract (Originalsprache)
Chikungunya virus (CHIKV) has been reported in over 120 countries and is the causative agent of Chikungunya fever. The debilitating nature of this disease, which can persist months to years after acute infection, drastically impacts the quality of life of patients. Yet, specific antivirals are lacking for the treatment of this disease, which makes the search for new drugs necessary. In this context, the nsP2 protease emerges as an attractive therapeutic target, and drug repurposing strategies have proven to be valuable. Therefore, we combined in silico and in vitro methods to identify known drugs as potential CHIKV nsP2 protease inhibitors with antiviral properties within DrugBank. Herein, we developed a hybrid virtual screening pipeline comprising pharmacophore- and target-based screening, drug-like, and pharmaceutical filtering steps. Six virtual hits were obtained, and two of them, capecitabine (CPB) and oxibendazole (OBZ), were evaluated against CHIKV replication in Vero cells. CPB did not present antiviral activity, whereas OBZ inhibited the replication of two different strains of CHIKV, namely, 181-25 (Asian genotype) and BRA/RJ/18 (clinical isolate from ECSA genotype). OBZ showed potent antiviral activity against the CHIKV BRA/RJ/18 (EC50 = 11.4 μM) with a high selectivity index (>44). Analogs of OBZ (albendazole, fenbendazole, and mebendazole) were also evaluated, but none exhibited anti-CHIKV activity, and further, their stereoelectronic features were analyzed. Additionally, we observed that OBZ acts mainly at post-entry steps. Hence, our results support further in vivo studies to investigate the antiviral potential of OBZ, which offers a new alternative to fight CHIKV infections.
Autor:innen und Institutionen
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro CEP 24210-201, Brazil.
- Gerência de Desenvolvimento Tecnológico, Instituto Vital Brazil, Niterói, Rio de Janeiro 24230-410, Brazil.
- Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, United States.
- Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana 47907, United States.
- Instituto de Biodiversidade e Sustentabilidade (NUPEM), Campus Macaé, Universidade Federal do Rio de Janeiro, Rio de Janeiro CEP 27965-045, Brazil.
- Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro CEP 24210-201, Brazil.
ORCID-Profile: Vitor W Rabelo, Richard J Kuhn, Izabel C N P Paixão
Förderung
- National Institute of Allergy and Infectious Diseases
- Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro
Zitieren
APA
Rabelo, V. W., Sanchez-Nuñez, M. L., Corrêa-Amorim, L. S., Kuhn, R. J., Abreu, P. A., & Paixão, I. C. N. P. (2024). In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus. ACS Omega, 9(25), 27632-27642. https://doi.org/10.1021/acsomega.4c03417
Vancouver
Rabelo VW, Sanchez-Nuñez ML, Corrêa-Amorim LS, Kuhn RJ, Abreu PA, Paixão ICNP. In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus. ACS Omega. 2024;9(25):27632-27642. doi:10.1021/acsomega.4c03417
BibTeX
@article{Rabelo2024,
author = {Rabelo, Vitor W and Sanchez-Nuñez, Maria Leonisa and Corrêa-Amorim, Leonardo S and Kuhn, Richard J and Abreu, Paula A and Paixão, Izabel C N P},
title = {In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus},
journal = {ACS Omega},
year = {2024},
volume = {9},
number = {25},
pages = {27632--27642},
doi = {10.1021/acsomega.4c03417}
}
EUVIMED